Sotrovimab (Gen1)

Phase 2

Vir Biotechnology, Inc. (VIR)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Covid19

HSCSWConvalescent Plasma

Phase 3

View Full Landscape

Drug Information

Target Indication

Covid19

Clinical Trial

NCT04779879

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/17/2021

Xevudy

Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VIR

Vir Biotechnology, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

TobevibartPhase 3

Viral Hepatitis

ElebsiranPhase 3

Viral Hepatitis